Marie-Cardine Aude, Berrebi Dominique, Orbach Daniel
CHU Charles-Nicolle, service d'immuno-hémato-oncologie pédiatrique, Rouen, France.
Bull Cancer. 2011 Feb;98(2):209-16. doi: 10.1684/bdc.2011.1311.
The paediatric rare tumours group from the Société française des cancers de l'enfant makes syntheses and guidelines for diagnosis and treatment for localized paediatric inflammatory myofibroblastic tumours according to international articles.
All ages are concerning. Localizations are ubiquitous, more frequently in the superior and inferior airway. Histology showed a majority of fusiform cells, corresponding to myofibroblastic cells and an inflammatory infiltrate. Inflammatory myofibroblastic tumour diagnosis should only be confirmed in the absence of sarcoma molecular markers.
Distinction between inflammatory myofibroblastic tumour and sarcoma is essential due to the different care. The curative treatment of inflammatory myofibroblastic tumour consists on surgery with before or after corticotherapy. In case of unresectability, chemotherapy may be helpful to avoid mutilating surgery.
法国儿童癌症协会的儿科罕见肿瘤小组根据国际文献对局限性儿科炎性肌纤维母细胞瘤的诊断和治疗进行综述并制定指南。
各年龄段均有涉及。肿瘤可发生于全身各处，在上、下呼吸道更为常见。组织学检查显示多数为梭形细胞，即肌纤维母细胞，伴有炎性浸润。炎性肌纤维母细胞瘤的诊断仅在无肉瘤分子标志物时才能确定。
由于治疗方式不同，区分炎性肌纤维母细胞瘤和肉瘤至关重要。炎性肌纤维母细胞瘤的根治性治疗包括手术，术前或术后可进行皮质激素治疗。若无法切除，化疗可能有助于避免进行致残性手术。
